ACCELERATE DIAGNOSTICS INC. overview

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance PR Newswire TUCSON, Ariz., March 21, 2025 TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance....

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results PR Newswire TUCSON, Ariz., March 21, 2025 TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024 . 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million , compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower...

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results PR Newswire TUCSON, Ariz., Jan. 10, 2025 TUCSON, Ariz. , Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended...

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results PR Newswire TUCSON, Ariz., Nov. 7, 2024 TUCSON, Ariz. , Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024 . "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVE TM system and the Gram-Negative assay. This quarter also marked a...

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results PR Newswire TUCSON, Ariz., Oct. 25, 2024 TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024 , at 4:30 p.m. Eastern Time to review 2024 third quarter results. To listen to the audio webcast online, visit ir.axdx.com . A replay of the audio webcast will be available for 30 days. To listen by phone, dial...

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System PR Newswire TUCSON, Ariz., Sept. 30, 2024 An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper ® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that...

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results PR Newswire TUCSON, Ariz., Aug. 8, 2024 TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024 . "During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVE TM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical...

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial PR Newswire TUCSON, Ariz., Aug. 8, 2024 TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC")...